标题:P-glycoprotein-evading anti-tumor activity of a novel tubulin and HSP90 dual inhibitor in a non-small-cell lung cancer model
作者:Zhang,Q.;Zhai,S.;Li,L.;Li,X.;Jiang,C.;Zhang,C.;Yan,B.
作者机构:[Zhang, Q] School of Chemistry and Chemical Engineering, Shandong University, Jinan, 250100, China;[ Zhai, S] School of Chemistry and Chemical Enginee 更多
通讯作者:Yan, B
通讯作者地址:[Yan, B]Shandong Univ, Sch Chem & Chem Engn, Jinan 250100, Peoples R China.
来源:Journal of pharmacological sciences
出版年:2014
卷:126
期:1
页码:66-76
DOI:10.1254/jphs.14050FP
关键词:HSP90;Microtubule;Multidrug resistance;Non-small-cell lung cancer;P-glycoprotein
摘要:P-glycoprotein (P-gp)-induced drug resistance is a major road block for successful cancer chemotherapy. Through phenotypic screening, the compound 2-(2-chlorophenylimino)-5-(4-dimethylaminobenzylidene)thiazolidin-4-one (CDBT) was discovered to have potent anti-tumor activity in P-gp over-expressing drug-resistant non-small-cell lung cancer (NSCLC) H460TaxR cells. Here, we report mechanistic investigations of the P-gp-evading anti-tumor activity of CDBT. CDBT is evidently not a P-gp substrate and escapes the P-gp efflux pump. As a novel microtubule and heat shock protein 90 (HSP90) dual targeting inhibitor, CDBT causes the destabilization of microtubules and degradation of HSP90 client proteins CRAF-1 and ERBB2, resulting in cell cycle arrest at the G2/M phase and apoptosis. Furthermore, CDBT effectively inhibits tumor growth by 60.4% relative to the vehicle control after intraperitoneal administration at 30 mg/kg for 11 days and shows no toxicity in normal tissues in the NSCLC H460TaxR xenograft mouse model. Our data suggest a novel drug discovery strategy to combat P-gp over-expressing drug-resistant NSCLC cancer cells with a single therapeutic agent.
收录类别:SCOPUS;SCIE
WOS核心被引频次:3
Scopus被引频次:4
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-84909966101&doi=10.1254%2fjphs.14050FP&partnerID=40&md5=cf7f8d70127cf89c78e95f51afdbf291
TOP